




# Supplementary Appendix

Supplement to: Kwok M, Korde N, Landgren O. Bortezomib to Treat the TEMPI Syndrome.

## Table of Contents:


Supplementary Appendix Figure 1 .....	2
Supplementary Appendix Figure 2 .....	3
Supplementary Appendix Figure 3 .....	4

**Supplementary Appendix Figure 1.**




**Footnote:** Bone marrow biopsy shows 50% overall cellularity defined by hematoxylin and eosin stain (A). CD138 stain highlights 10-15% plasma cells in the bone marrow (B). The plasma cells are negative for kappa light chains (C) and are positive for lambda light chains (D).

**Supplementary Appendix Figure 2.**



**Footnote:** A baseline (A) CT scan of the abdomen demonstrates bilateral perinephric fluid collections (arrows). After 4 cycles of bortezomib therapy (B), the left-sided perinephric fluid collection is decreased in size the right side is stable.

**Supplementary Appendix Figure 3.**



**Footnote:** The patient had telangiectasias that were most notable on the chest (A) and nose (B).

Telangiectasias are stable after 4 cycles of bortezomib therapy.